Physician profile
Bonnie Cramer
NPI 1679120588
$2,476.78
in general payments reported to CMS, 2019-2025
26 companies · $998 in 2025
The $998 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $295 · 2022: $249 · 2023: $214 · 2024: $720 · 2025: $998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,916 · Education: $16.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,915.60 |
| Education | $16.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $943.70 | 2021-2025 | |
| Ardelyx, INC. | $257.44 | 2024-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $230.50 | 2021-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $136.11 | 2021-2025 | Xifaxan |
| Ferring Pharmaceuticals INC. | $94.69 | 2021-2024 | Rebyota |
| Janssen Biotech, INC. | $89.70 | 2022-2025 | Tremfya |
| Boston Scientific Corporation | $73.04 | 2021 | |
| Genzyme Corporation | $59.13 | 2024-2025 | |
| Intercept Pharmaceuticals, INC. | $58.03 | 2024-2025 | |
| Celltrion USA INC. | $54.86 | 2024-2025 | Vegzelma, Zymfentra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $50.34 | 2024-2025 | Lifevest |
| Phathom Pharmaceuticals, INC. | $43.42 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $42.02 | 2023-2024 | Dificid |
| Madrigal Pharmaceuticals | $40.90 | 2025 | Rezdiffra |
| Nestle Healthcare Nutrition INC. | $40.14 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $37.58 | 2025 | Omvoh |
| Biomerieux INC | $35.12 | 2024 | Filmarray Bcid2 Control Panel M416 |
| Regeneron Healthcare Solutions, INC. | $32.39 | 2022 | |
| Ironwood Pharmaceuticals, INC | $31.28 | 2024 | |
| Novo Nordisk INC | $27.61 | 2025 | Wegovy |
| Gilead Sciences, INC. | $22.19 | 2021 | |
| Vivus LLC | $18.62 | 2024 | Qsymia |
| Aimmune Therapeutics, INC. | $16.67 | 2025 | Zenpep |
| Braintree Laboratories, INC. | $14.80 | 2024 | Sutab, Suflave |
| Redhill Biopharma INC. | $13.84 | 2021 | |
| Axonics, INC. | $12.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bonnie Cramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.